This content is machine translated Type 2 diabetes The cardiovascular diabetic patient – an interdisciplinary challenge A patient with type 2 diabetes is 2-3 times more likely to have a myocardial infarction or stroke than people without diabetes. Cardiovascular disease accounts for up to 50% of… CME-Test
View Post 6 min This content is machine translated KESIMPTA® (ofatumumab) for the treatment of relapsing-remitting multiple sclerosis High efficacy with good tolerability For patients with relapsing-remitting multiple sclerosis (RMS), KESIMPTA® (ofatumumab) has recently become the first subcutaneous antibody-based therapy option available. In the ASCLEPIOS I and II trials, ofatumumab was shown to…
View Post 5 min This content is machine translated Safety Check Selectivity as a distinguishing feature Like any form of intervention in the human immune system, therapy with Ozanimod carries certain risks. In particular, infections and adverse cardiac effects represent previously known side effects of treatment…
View Post 4 min This content is machine translated Efficacy Check Multiple levels of effectiveness The two completed phase III studies SUNBEAM [1] and RADIANCE [2] were able to demonstrate the efficacy of the new active substance in the area of other – radiological and…
View Post 5 min This content is machine translated Ozanimod A new player in MS therapy With the recently approved ozanimod, another potent compound for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) is entering the Swiss market. The oral sphingosine-1-phosphate (S1P) receptor modulator demonstrated…
View Post 10 min This content is machine translated Chronic inflammatory bowel disease (CED) Modern “State-of-the-Art” Pharmacotherapy – an Update Modern approaches to the treatment of inflammatory bowel disease (IBD) are based on the motto “treat-to-target”, whereby in addition to symptom relief and induction of disease remission, the aim nowadays… CME-Test
View Post 3 min This content is machine translated Diabetes Management Type 1 diabetics benefit from additive oral therapy Type 1 diabetics with obesity in whom insulin therapy alone is insufficient for glycemic control may additionally benefit from oral treatment with an SGLT2 inhibitor. Recent study results show good…
View Post 4 min This content is machine translated Diabetes Cases Intensification of the treatment of type 2 diabetes mellitus In a 63-year-old patient, although glucose metabolic control is quite good, there is still potential for optimizing diabetes management. Thus, with a change in therapy, his pre-existing cardiovascular conditions can…
View Post 4 min This content is machine translated SGLT-2 inhibitors and GLP-1-RA How they can protect against diabetic sequelae In recent years, numerous new glucose-lowering agents have been developed. SGLT-2 inhibitors and GLP-1 receptor agonists have demonstrated cardiovascular and nephroprotective effects in large clinical endpoint studies. The variety of…
View Post 4 min This content is machine translated Undifferentiated rheumatoid arthritis Early detection as the basis for adequate therapy In the case of arthritic complaints, regular progress assessment using the ACR/EULAR criteria is significant so that the time for disease-modifying therapy is not missed. Controlling disease activity at an…
View Post 1 min This content is machine translated MS therapy today A new player in MS therapy With the recently approved ozanimod, another highly potent agent for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) is entering the Swiss market. The oral sphingosine-1-phosphate (S1P) receptor modulator…
